Clinical Trial

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2011-11-18; most recent amendment 2025-09-11.
Trial Details
NCT Number NCT01475123
Lead Sponsor Kumamoto University
Conditions Coronary Artery Disease, End Stage Renal Disease
Enrollment 268 participants
Start Date 2008-06
Primary Completion 2011-06 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-17